Pharmacological effect and clinical evaluation of rezafungin in treating candidemia and invasive candidiasis

doi:10.19803/j.1672-8629.20230470

Abstract

Abstract: Rising global fungal infections represent a significant public health burden, which are among the most difficult diseases to manage in humans. Candida spp, a major aetiologic agent of fungal infections, can cause severe invasive and systemic diseases that can even be deadly. On March 22, 2023, the FDA approved a novel echinocandin antifungal rezafungin to treat candidemia and invasive candidiasis. Clinical studies have shown that rezafungin has a good efficacy and safety for candidiasis infections. This review describes its pharmacological action, clinical evaluation, safety, usage and dosage.

Key words: echinocandin, rezafungin, candidemia, invasive candidiasis, pharmacological effects, clinical evaluation, safety

CLC Number:

R994.11
R978

GU Xiaotong, SUN Xuelin, ZHENG Li. Pharmacological effect and clinical evaluation of rezafungin in treating candidemia and invasive candidiasis[J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 469-472.

Add to citation manager EndNote|Ris|BibTeX

URL: https://www.zgywjj.com/EN/10.19803/j.1672-8629.20230470

https://www.zgywjj.com/EN/Y2024/V21/I4/469

References

[1] VITIELLO A, FERRARA F, BOCCELLINO M, et al.Antifungal drug resistance: an emergent health threat[J]. Biomedicines, 2023, 11(4): 1063.
[2] BARANTSEVICH N, BARANTSEVICH E.Diagnosis and treatment of invasive candidiasis[J]. Antibiotics, 2022, 11(6): 718.
[3] FIORITI S, BRESCINI L, PALLOTTA F, et al.Antifungal combinations against candida species: from bench to bedside[J]. Journal of Fungi, 2022, 8(10): 1077.
[4] BILAL H, SHAFIQ M, HOU B, et al.Distribution and antifungal susceptibility pattern of candida species from mainland China: a systematic analysis[J]. Virulence, 2022, 13(1): 1573-1589.
[5] RODRÍGUEZ-CASTAÑO GP, ROSENAU F, STÄNDKER L, et al. Antimicrobial peptides: avant-garde antifungal agents to fight against medically important candida species[J]. Pharmaceutics, 2023, 15(3): 789.
[6] WHO. WHO fungal priority pathogens list to guide research, development and public health action[R]. WHO, 2022.
[7] HU X, YANG P, CHAI C, et al.Structural and mechanistic insights into fungal β-1, 3-glucan synthase FKS1[J]. Nature, 2023, 616(7955): 190-198.
[8] MROCZYŃSKA M, BRILLOWSKA-DĄBROWSKA A. Review on current status of echinocandins use[J]. Antibiotics, 2020, 9(5): 227.
[9] ZHANG SQ, CHENG DY.Research progress in echinocandin antifungal drugs[J]. Medical Recapitulate(医学综述), 2020, 26(5): 986-990.
[10] TANG L, QIAN Q, HU N, et al.Progress in population pharmacokinetic study of echinocandin antifungal drugs intransplant recipients[J]. Clinical Medication Journal(临床药物治疗杂志), 2023, 21(2): 17-21.
[11] FAN X, GUO LN, YANG Y, et al.Epidemiology and antifungal susceptibilities of yeast isolates causing invasive infections[J]. Chinese Journal of Mycology(中国真菌学杂志), 2020, 15(1): 10-14.
[12] LI S, DAI LB, YAO HT, et al.Meta-analysis of the efficacy and safety of echinocandins as antifungal agents in the prevention of invasive candidiasis[J]. China Pharmacy(中国药房), 2020, 31(1): 104-109.
[13] ZENG Y, GUAN ZM, HUANG TT.Cure rate of echinocandins versus non-echinocandins in the treatment of invasive candidosis infection and candidemia: Meta-analysis[J]. China Pharmacy(中国药房), 2014, 25(32): 3038-3041.
[14] TIAN C, SHI Q, WANG XL.The efficacy and safety of echinocandins to invasive candidiasis in pediatric patients: a systematic review and meta-analysis[J]. Chinese Pharmaceutical Journal(中国药学杂志), 2019, 54(8): 659-664.
[15] SYED YY.Rezafungin: first approval[J]. Drugs, 2023, 83(9): 833-840.
[16] GARCIA-EFFRON G.Rezafungin-mechanisms of action, susceptibility and resistance: similarities and differences with the other echinocandins[J]. Journal of Fungi, 2020, 6(4): 262.
[17] ZHAO Y, PERLIN DS.Review of the novel echinocandin antifungal rezafungin: animal studies and clinical data[J]. Journal of Fungi, 2020, 6(4): 192.
[18] HOENIGL M, SPRUTE R, EGGER M, et al.The antifungal pipeline: Fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin[J]. Drugs, 2021, 81(15): 1703-1729.
[19] FDA. REZZAYO[EB/OB]. (2023-03-23)[2023-06-22]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217417s000lbl.pdf.
[20] THOMPSON GR, SORIANO A, SKOUTELIS A, et al.Rezafungin versus caspofungin in a phase 2, randomized, double-blind study for the treatment of candidemia and invasive candidiasis: the STRIVE trial[J]. Clinical Infectious Diseases, 2021, 73(11): e3647-e3655.
[21] THOMPSON III G, SORIANO A, CORNELY O.ReSTORE: efficacy and safety results of the phase 3, noninferiority trial of rezafungin in the treatment of candidemia and/or invasive candidiasis (IC)[C]. ECCMID, 2022.
[22] FLANAGAN S, WALKER H, ONG V, et al.Absence of clinically meaningful drug-drug interactions with rezafungin: outcome of investigations[J]. Microbiology Spectrum, 2023, 11(3): e0133923.
[23] LOGAN A, WOLFE A, WILLIAMSON JC.Antifungal resistance and the role of new therapeutic agents[J]. Current Infectious Disease Reports, 2022, 24(9): 105-116.